Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Cornell Pochily Investment Advisors Inc.

Cornell Pochily Investment Advisors Inc. decreased its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 11.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,980 shares of the medical equipment provider’s stock after selling 918 shares during the period. Cornell Pochily Investment Advisors Inc.’s holdings in Zimmer Biomet were worth $850,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. Vanguard Group Inc. increased its holdings in Zimmer Biomet by 19.0% in the first quarter. Vanguard Group Inc. now owns 23,102,761 shares of the medical equipment provider’s stock valued at $2,954,843,000 after buying an additional 3,695,510 shares in the last quarter. BlackRock Inc. increased its holdings in Zimmer Biomet by 5.2% in the second quarter. BlackRock Inc. now owns 22,098,606 shares of the medical equipment provider’s stock valued at $3,217,557,000 after buying an additional 1,094,431 shares in the last quarter. State Street Corp increased its holdings in Zimmer Biomet by 3.6% in the second quarter. State Street Corp now owns 9,056,896 shares of the medical equipment provider’s stock valued at $1,320,827,000 after buying an additional 318,082 shares in the last quarter. American Century Companies Inc. increased its stake in shares of Zimmer Biomet by 21.2% during the 3rd quarter. American Century Companies Inc. now owns 4,863,741 shares of the medical equipment provider’s stock worth $545,809,000 after purchasing an additional 852,186 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Zimmer Biomet by 2.3% during the 1st quarter. Geode Capital Management LLC now owns 4,315,167 shares of the medical equipment provider’s stock worth $556,244,000 after purchasing an additional 96,028 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Wall Street Analyst Weigh In

ZBH has been the topic of a number of analyst reports. Morgan Stanley raised their target price on shares of Zimmer Biomet from $120.00 to $125.00 and gave the stock an “equal weight” rating in a research report on Monday, December 4th. Raymond James raised their target price on shares of Zimmer Biomet from $133.00 to $137.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. StockNews.com lowered shares of Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a research report on Monday, February 19th. Evercore ISI lowered shares of Zimmer Biomet from an “outperform” rating to an “inline” rating and decreased their target price for the stock from $135.00 to $125.00 in a research report on Thursday, January 4th. Finally, Barclays lifted their price target on shares of Zimmer Biomet from $120.00 to $130.00 and gave the company an “underweight” rating in a report on Monday, February 12th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $137.84.

Zimmer Biomet Stock Up 0.0 %

ZBH stock traded up $0.03 during trading hours on Thursday, hitting $132.64. The company’s stock had a trading volume of 419,545 shares, compared to its average volume of 1,545,005. The company has a quick ratio of 0.78, a current ratio of 1.61 and a debt-to-equity ratio of 0.39. The company has a market capitalization of $27.20 billion, a PE ratio of 27.12, a price-to-earnings-growth ratio of 2.35 and a beta of 1.01. Zimmer Biomet Holdings, Inc. has a 12 month low of $102.00 and a 12 month high of $149.25. The stock has a 50 day moving average price of $125.25 and a two-hundred day moving average price of $118.03.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.15 by $0.05. The business had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.93 billion. Zimmer Biomet had a net margin of 13.85% and a return on equity of 12.79%. Zimmer Biomet’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.88 EPS. On average, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.72%. The ex-dividend date is Wednesday, March 27th. Zimmer Biomet’s dividend payout ratio (DPR) is currently 19.63%.

Insider Buying and Selling

In other Zimmer Biomet news, VP Chad F. Phipps sold 26,156 shares of the stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the sale, the vice president now owns 44,145 shares of the company’s stock, valued at approximately $5,677,929.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.95% of the stock is currently owned by corporate insiders.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.